Takeda Pharmaceutical Co. Ltd. Sponsored ADR Aktie News

Takeda Pharmaceuticals is downgraded from buy to hold after reaching 52-week highs, with valuation no longer compelling. TAK's Q3 earnings were resilient despite US revenue declining 9.1%; margin improvement and international growth offset generic headwinds. Entyvio remains the key growth driver, but lack of pipeline blockbusters and US weakness limit near-term catalysts.

Takeda Pharmaceutical Company Limited (TAK) Q3 2026 Earnings Call Transcript

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The company raised its full-yea...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, approved as replacement therapy for people two years of age and older with primary immunodeficiency (PI). GAMMAGARD LIQUID ERC is a liquid immunoglobulin therapy ...

Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class sub...

Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial intelligence, succeeded in two late-stage studies.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment.